https://clicktherapeutics.com

Click Therapeutics - Where Science Meets SoftwareWe combine neuroscience with the power of software to create patient-centric digital treatments. Discover our prescription digital therapeutics and software-enhanced drug therapies.Click Therapeutics - Where Science Meets SoftwarePlatformProductsClick SEInsightsAboutCollaborate with usWhat’s new?Where science meetssoftware.Software as treatment. Delivered to your phone. Prescribed by your physician.Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.Read more about usDigital treatments, tangible outcomes.We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs.Learn more about products on our platformClick SEMedicine just got a digital upgrade: Software-Enhanced Drugs™Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, designed to deliver added clinical benefit to patients compared to drug alone.Discover Click SE™ One powerful platform. Many ways to treat disease.Our multimodal, platform-based approach targets disease and drives outcomes from multiple different angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions.Learn more about our platformLatest at ClickView all02.12.2025Prescription Digital TherapeuticsPodcastOpportunities Abound for PDTs, with Click Therapeutics, Syneos Health PodcastBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer01.30.2025Software-Enhanced DrugsClick SEPDURSThe Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs12.30.2024TechnologyDepressionPrescription Digital TherapeuticsThe Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For AllBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer11.21.2024Software-Enhanced DrugsClick SEPDURSMedicine just got a digital upgrade: Software-Enhanced Drugs™By David Benshoof KleinFounder & CEO11.11.2024Software-Enhanced DrugsClick SEDrugs Are Becoming ‘Smarter.’ Here’s HowBy David Benshoof KleinFounder & CEO10.24.2024Software-Enhanced DrugsClick SEPDURSPodcastCould PDURS Be the Game Changer to Unlock Digital Therapeutics?By Randall StanickyChief Financial Officer10.23.2024Prescription Digital TherapeuticsPodcastPsychiatrySoftware as Medicine: Prescription Digital Therapeutics with Dr. Shaheen Lakhan, Alluminate PodcastBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer10.08.2024SchizophreniaA Personal Call for Mental Health ParityBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer08.02.2024Software-Enhanced DrugsClick SEThe Future of Smart Drugs: FDA’s New Guidance on Digital Therapeutics Could Revolutionize Pharma and Patient CareBy Randall StanickyChief Financial Officer08.01.2024FDASoftware-Enhanced DrugsClick SEPDURSThe FDA’s PDURS Guidance: What Manufacturers Need to KnowBy Austin SpeierChief Strategy Officer02.12.2025Prescription Digital TherapeuticsPodcastOpportunities Abound for PDTs, with Click Therapeutics, Syneos Health PodcastBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer01.30.2025Software-Enhanced DrugsClick SEPDURSThe Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs12.30.2024TechnologyDepressionPrescription Digital TherapeuticsThe Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For AllBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer11.21.2024Software-Enhanced DrugsClick SEPDURSMedicine just got a digital upgrade: Software-Enhanced Drugs™By David Benshoof KleinFounder & CEO11.11.2024Software-Enhanced DrugsClick SEDrugs Are Becoming ‘Smarter.’ Here’s HowBy David Benshoof KleinFounder & CEO10.24.2024Software-Enhanced DrugsClick SEPDURSPodcastCould PDURS Be the Game Changer to Unlock Digital Therapeutics?By Randall StanickyChief Financial Officer10.23.2024Prescription Digital TherapeuticsPodcastPsychiatrySoftware as Medicine: Prescription Digital Therapeutics with Dr. Shaheen Lakhan, Alluminate PodcastBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer10.08.2024SchizophreniaA Personal Call for Mental Health ParityBy Shaheen Lakhan, MD, PhD, FAANChief Medical Officer08.02.2024Software-Enhanced DrugsClick SEThe Future of Smart Drugs: FDA’s New Guidance on Digital Therapeutics Could Revolutionize Pharma and Patient CareBy Randall StanickyChief Financial Officer08.01.2024FDASoftware-Enhanced DrugsClick SEPDURSThe FDA’s PDURS Guidance: What Manufacturers Need to KnowBy Austin SpeierChief Strategy OfficerView allRecent publicationsView all01.27.2025SchizophreniaCT-155Prescription Digital TherapeuticsPeer-reviewed ManuscriptsEstablishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm StudiesBy Snipes et al.01.10.2025Prescription Digital TherapeuticsEditorial: Prescription digital therapeutics in psychiatryBy Colbert et al.08.20.2024CT-152RejoynDepressionPrescription Digital TherapeuticsPeer-reviewed ManuscriptsEvaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote StudyBy Rothman et al.04.13.2024Prescription Digital TherapeuticsMigrainePosters & PresentationsMigraine-specific Health Care Resource Utilization (HCRU) in the US: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer DatabasesBy Petrova et al.04.13.2024MigraineCT-132Posters & PresentationsComparison of Health Care Resource Utilization (HCRU) of Chronic Migraine and Other Migraine Patients: A Retrospective Claims Analysis.By Kuka et al.04.13.2024MigraineCT-132Posters & PresentationsUS Economic Burden of Migraine: A Retrospective Claims AnalysisBy Besedina et al.04.09.2024CT-132MigrainePosters & PresentationsA Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care (P1-12.005)By Gupta et al.02.21.2024CT-132MigrainePosters & PresentationsEfficacy of Recruitment Techniques for a Decentralized Trial of a Digital Therapeutic for MigraineBy Colbert et al.09.06.2023SchizophreniaPrescription Digital TherapeuticsPosters & PresentationsA Pilot Study to Assess if Patients With Schizophrenia can Form a Working Alliance With a Digital TherapeuticBy Campellone et al.06.15.2023MigrainePosters & PresentationsCT-132Current Migraine Headache Treatment Characteristics in a Nationally Representative Sample of U.S. AdultsBy Gupta et al.01.27.2025SchizophreniaCT-155Prescription Digital TherapeuticsPeer-reviewed ManuscriptsEstablishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm StudiesBy Snipes et al.01.10.2025Prescription Digital TherapeuticsEditorial: Prescription digital therapeutics in psychiatryBy Colbert et al.08.20.2024CT-152RejoynDepressionPrescription Digital TherapeuticsPeer-reviewed ManuscriptsEvaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote StudyBy Rothman et al.04.13.2024Prescription Digital TherapeuticsMigrainePosters & PresentationsMigraine-specific Health Care Resource Utilization (HCRU) in the US: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer DatabasesBy Petrova et al.04.13.2024MigraineCT-132Posters & PresentationsComparison of Health Care Resource Utilization (HCRU) of Chronic Migraine and Other Migraine Patients: A Retrospective Claims Analysis.By Kuka et al.04.13.2024MigraineCT-132Posters & PresentationsUS Economic Burden of Migraine: A Retrospective Claims AnalysisBy Besedina et al.04.09.2024CT-132MigrainePosters & PresentationsA Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care (P1-12.005)By Gupta et al.02.21.2024CT-132MigrainePosters & PresentationsEfficacy of Recruitment Techniques for a Decentralized Trial of a Digital Therapeutic for MigraineBy Colbert et al.09.06.2023SchizophreniaPrescription Digital TherapeuticsPosters & PresentationsA Pilot Study to Assess if Patients With Schizophrenia can Form a Working Alliance With a Digital TherapeuticBy Campellone et al.06.15.2023MigrainePosters & PresentationsCT-132Current Migraine Headache Treatment Characteristics in a Nationally Representative Sample of U.S. AdultsBy Gupta et al.View allCollaboratorsBy embracing collaborations that build on our unique areas of expertise, we’re powering a new era of medicine.ContactJoin us in our journey to raise the bar of modern medicine with software as treatments.Join usQ&AWhat are Prescription Digital Therapeutics (PDTs)?What is the Click SE™ offering?What are software-enhanced drug™ therapies?What is PDURS?How can pharma best leverage PDURS to benefit patients?What clinical outcomes can Click software deliver?What commercial outcomes can Click software deliver?How does IP work in the context of software-enhanced drug™ therapies?Learn more terminologyStay up to date with news and updatesNews | 03.19.2025Click Therapeutics Announces Series C, Dassault Systèmes and Medidata Make Strategic Investment Read moreInsight | 01.30.2025The Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs Read moreInsight | 12.30.2024The Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For All Read moreView what’s new at ClickAbout usClick SEInsightsPressPlatformOur productsContactTerms of useTeamClinical trialsTerminologyPrivacy policyCareersContact us:info@clicktherapeutics.combd@clicktherapeutics.compr@clicktherapeutics.comir@clicktherapeutics.comFollow our news© 2025 Click Therapeutics, Inc.enen1770850458https://clicktherapeutics.com

Рэдагаваць свой сайт?

Што ты робіш